Target intelligence / Profile preview

Dengue virus 1 structural protein

Molecular classification
Other
01

Overview

“Dengue virus 1 structural proteins” is a collective term referring to the three main structural proteins found in all dengue viruses, including type 1 (DENV1): the **capsid (C)**, **pre-membrane/membrane (prM/M)**, and **envelope (E)** proteins[4][3]. These proteins form the viral particle: the capsid protein encapsidates the viral RNA and interacts with the lipid membrane; the prM/M protein organizes the outer structure and aids in particle maturation; and the E protein mediates viral attachment, membrane fusion, and is the main antigenic determinant for neutralizing antibodies[4][3][1]. These structural proteins are key in the viral life cycle and represent major therapeutic and vaccine targets[3][4]. Drugs inhibiting their function have shown antiviral effects in laboratory experiments. However, “Dengue virus 1 structural proteins” is a grouping, not a single molecule or unified target, so is_incorrect should be set to true for target standardization purposes (preferred canonical forms should be for individual proteins such as “Dengue virus envelope protein,” “Dengue virus capsid protein,” etc.)[3]. If you require structured data for each individual protein (capsid, prM/M, or E), it is best to query those specifically.

Other names
Dengue structural proteinDengue virus type 1 structural proteinsDENV1 structural proteinsDengue virus capsid proteinDengue virus envelope proteinDengue virus membrane protein
02

Mechanism of action

Inhibition of capsid protein dimerization (ST-148) - Inhibition of envelope protein-mediated membrane fusion (various small molecules, including 3-110-22 and others)[3]

03

Biological functions

Viral assembly and morphogenesisViral entry and membrane fusionRNA encapsidation
04

Disease associations

Infection (Dengue fever, Dengue hemorrhagic fever)
05

Safety considerations

Drug specificity (potential cross-reactivity with host proteins)Antigenic variability between serotypesRisk of antibody-dependent enhancement if antibodies are generated against highly variable regions
06

Interacting drugs

ST-148

6 more in the full profile.

Beyond the preview

Go deeper on Dengue virus 1 structural protein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dengue virus 1 structural protein.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call